title: Tumor lysis syndrome: pathophysiology, definition, and alternative treatment approaches.
abstract: Tumor lysis syndrome (TLS), a life threatening metabolic syndrome seen in malignancies with high tumor burden, is reviewed in this article. The new Cairo and Bishop classification system is discussed as well as the clinical management of this syndrome. Special emphasis is placed on the use of a relatively new agent, rasburicase, as an alternative to allopurinol in the management of TLS-associated hyperuricemia.
authors.affiliation: Division of Pediatric Hematology, Columbia University, 180 Fort Washington Avenue, New York, NY 10032, USA.
authors.forename: Gustavo
authors.initials: G
authors.lastname: Del Toro
authors.forename: Erin
authors.initials: E
authors.lastname: Morris
authors.forename: Mitchell S
authors.initials: MS
authors.lastname: Cairo
mesh_terms: D003937:Diagnosis, Differential; D006801:Humans; D009369:Neoplasms / Q000150:complications; D009626:Terminology as Topic; D015275:Tumor Lysis Syndrome / Q000145:classification* / Q000188:drug therapy* / Q000503:physiopathology; D014503:Urate Oxidase / Q000627:therapeutic use*
chemical_list: C469709:rasburicase; D014503:Urate Oxidase